Why would an estimated glomerular filtration rate (eGFR) drop abruptly by more than 20 mL/min/1.73 m² and then rise again above 90 mL/min/1.73 m²?

Acute eGFR Drop Followed by Recovery: Common Causes and Clinical Significance

An eGFR that drops abruptly by more than 20 points and then recovers above 90 mL/min/1.73 m² most commonly reflects either medication-induced hemodynamic changes (particularly with RAAS inhibitors or SGLT2 inhibitors), acute volume depletion that resolves, or normal physiological fluctuation in kidney function measurements.

Medication-Induced Hemodynamic Changes

RAAS Inhibitors (ACE Inhibitors/ARBs)

The most clinically relevant cause is initiation of renin-angiotensin-aldosterone system (RAAS) inhibitors. An eGFR drop of 15-20% is anticipated and expected after starting ACE inhibitors or ARBs 1. This occurs due to:

• Reduction in intraglomerular pressure from efferent arteriole vasodilation
• Hemodynamic adjustment rather than actual kidney damage
• This phenomenon is transient and reversible when the medication is discontinued 1
• No loss of functioning nephrons occurs 1

Importantly, in the CONSENSUS trial, 11% of patients on enalapril experienced doubling of serum creatinine early in treatment, but serum creatinine returned to within 30% of baseline values in the majority of patients 1. The long-term slope of kidney function decline remains parallel after this initial drop, indicating kidney protection despite the acute decrease 1.

SGLT2 Inhibitors

SGLT2 inhibitors cause a temporary eGFR decrease of 15-25% that generally resolves in 1-3 months 2. This mechanism is similar to RAAS inhibitors:

• Decreased intraglomerular pressure
• Not a sign of acute kidney injury
• Trial evidence shows no increase or even reduction in actual kidney injury 2
• This eGFR reduction should not result in premature discontinuation 2

Volume Depletion and Prerenal States

Acute volume depletion from:

• Dehydration
• Diuretic use
• Gastrointestinal losses
• Reduced oral intake

When volume status is restored, eGFR rapidly returns to baseline. This represents prerenal azotemia rather than intrinsic kidney damage.

Normal Physiological Fluctuation

eGFR naturally fluctuates, and small variations are common and not necessarily indicative of true kidney disease progression 3, 4. Research demonstrates:

• Average eGFR variation of 4.8 mL/min/1.73 m² between measurements 5
• 45.8% of patients had eGFR changes greater than ±10 mL/min/1.73 m² between two measurements only 3 days apart 5
• These fluctuations reflect natural variations in serum creatinine levels 5

The magnitude of fluctuation increases with:

• Obesity 6
• Higher baseline eGFR 6
• Shorter time intervals between measurements 6

Clinical Interpretation Algorithm

When evaluating an acute eGFR drop with subsequent recovery:

1. Review medication history: Was a RAAS inhibitor or SGLT2 inhibitor started within the past 1-3 months?

   • If yes: This is expected and beneficial long-term 1, 2
   • Continue medication unless eGFR drops >30% or other complications arise 2

2. Assess volume status: Was there dehydration, illness, or diuretic adjustment?

   • If yes: Recovery with rehydration confirms prerenal cause
   • No intervention needed beyond addressing underlying cause

3. Evaluate measurement reliability:

   • Single measurements are unreliable 6, 5
   • Construct long-term eGFR plots using all available values to minimize fluctuation effects 6
   • Confidence in assessing true changes increases with more measurements over longer duration 3, 4

4. Check for true progression markers:

   • A sustained decline >5 mL/min/1.73 m²/year indicates rapid progression 3, 4
   • Drop in GFR category with ≥25% decline from baseline defines certain progression 3, 4

Critical Pitfalls to Avoid

Do not discontinue RAAS inhibitors or SGLT2 inhibitors for expected hemodynamic eGFR drops 1, 2. These medications provide long-term kidney and cardiovascular protection despite initial eGFR reduction. The acute drop represents beneficial hemodynamic changes, not kidney damage.

Do not interpret single eGFR measurements as definitive evidence of kidney disease progression or recovery 6, 5. Natural fluctuation can exceed 10 mL/min/1.73 m² and obscure true trends.

Do not assume all eGFR drops require immediate intervention. Distinguish between:

• Expected medication effects (observe and continue)
• Reversible prerenal states (address underlying cause)
• True acute kidney injury (requires investigation)

When to Investigate Further

Consider additional workup if:

• eGFR drop >30% within 3 months of starting RAAS inhibitor or SGLT2 inhibitor 2
• Sustained decline persists beyond expected timeframe (>3 months for SGLT2i, variable for RAAS inhibitors)
• Accompanying symptoms suggesting intrinsic kidney disease
• Development of significant hyperkalemia
• New or worsening proteinuria